课题基金 / 基金详情

NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS

NEOPLASTIC AND NORMAL T CELL DIFFERENTIATION ANTIGENS
肿瘤和正常 T 细胞分化抗原
批准号:
3181920
负责人:
JOHN G. FRELINGER
金额:
$10.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-01-01 至 1988-12-31

项目摘要

项目成果

JOHN G. FRELINGER的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究的目的是获得基本的结构、遗传和 一种新的小鼠T细胞分化抗原的生物学信息 (BM100)。用单抗筛查正常和非霍奇金淋巴瘤的初步结果 肿瘤细胞提示BM100是T细胞特异性的,除非它是 在很高比例的骨髓细胞上发现。基于这一发现, 似乎BM100存在于前T细胞上。这一假设将是 通过包括流式细胞术在内的多种技术进行检查, 免疫印迹和骨髓嵌合体。关于的结构信息 蛋白质将使用免疫印迹、凝集素柱、放射性标记、 以及一维和二维凝胶分析。编码BM100的cDNA 将使用cDNA表达载体从T细胞肿瘤中分离抗原 Lambda gt11。这些克隆将被测序并用于遗传图谱 学习。它们还将被用于分离和鉴定基因组 克隆人。BM100很有趣,因为它可能代表着最早的 T细胞的标记物。BM100也很有趣,因为它可能 代表人类抗原(GpL115)的小鼠同源物。GpL115 最近发现,慢性阻塞性肺疾病患者的分子水平发生了变化 Wiskott-Aldrich综合征,一种X连锁的免疫缺陷疾病,它 在其他缺陷中,T细胞异常,经常导致 淋巴网状恶性肿瘤。
英文摘要
The purpose of this research is to obtain basic structural, genetic, and biological information on a novel mouse T cell differentiation antigen (BM100). Initial findings using a monoclonal antibody to screen normal and neoplastic cells suggest that BM100 is T cell specific except that it is found on a high pecentage of bone marrow cels. Based on this finding it appears that BM100 is present on pre-T cells. This hypothesis will be examined by a combination of techniques including flow cytometry, immunoblots, and bone-marrow chimeras. Structural information on the protein will be obtained using immunoblots, lectin columns, radiolabelling, and one and two dimensional gel analysis. The cDNAs encoding the BM100 antigen will be isolated from a T cell tumor using a cDNA exprssion vector lambda gt11. These clones will be sequenced and used in genetic mapping studies. They will also be used to isolate and characterize genomic clones. The BM100 is interesting since it may represent the earliest marker of T lineage cells. The BM100 is also interesting since it may represent the mouse homolog of a human antigen (gpL115). The gpL115 molecule has recently been found to be altered in patients with Wiskott-Aldrich Syndrome, an X-linked immunodeficiency disorder, which among other defects has T cell abnormalities and often leads to lymphoreticular malignancies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing novel strategies for altering the cytokine microenvironment of tumors
  • 批准号:
    8957973
  • 项目类别:
  • 资助金额:
    $16.69万
  • 财政年份:
    2015
  • 负责人:
    JOHN G. FRELINGER
  • 依托单位:
Developing novel strategies for altering the cytokine microenvironment of tumors
  • 批准号:
    9105713
  • 项目类别:
  • 资助金额:
    $20.03万
  • 财政年份:
    2015
  • 负责人:
    JOHN G. FRELINGER
  • 依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
  • 批准号:
    2517707
  • 项目类别:
  • 资助金额:
    $18.64万
  • 财政年份:
    1996
  • 负责人:
    JOHN G. FRELINGER
  • 依托单位:
TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER
  • 批准号:
    2902203
  • 项目类别:
  • 资助金额:
    $23.5万
  • 财政年份:
    1996
  • 负责人:
    JOHN G. FRELINGER
  • 依托单位:
海外基金